{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+injection+%28intravenous+solution%29&page=4", "query": { "intervention": "Placebo injection (intravenous solution)", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 132, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+injection+%28intravenous+solution%29&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+injection+%28intravenous+solution%29&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T09:07:26.139Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01673828", "title": "Allopregnanolone for the Treatment of Traumatic Brain Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Traumatic Brain Injury", "Posttraumatic Epilepsy" ], "interventions": [ { "name": "Allopregnanolone injection", "type": "DRUG" }, { "name": "Placebo injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael A. Rogawski, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 13, "start_date": "2013-04", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-10-07T09:07:26.139Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01673828" }, { "nct_id": "NCT04518410", "title": "ACTIV-2: A Study for Outpatients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Coronavirus", "Covid19" ], "interventions": [ { "name": "bamlanivimab 7000mg", "type": "BIOLOGICAL" }, { "name": "BRII-196+BRII-198", "type": "BIOLOGICAL" }, { "name": "AZD7442 (IV)", "type": "BIOLOGICAL" }, { "name": "AZD7442 (IM)", "type": "BIOLOGICAL" }, { "name": "SNG001", "type": "DRUG" }, { "name": "Camostat", "type": "DRUG" }, { "name": "BMS-986414 + BMS-986413", "type": "BIOLOGICAL" }, { "name": "SAB-185 (3,840 Units/kg)", "type": "BIOLOGICAL" }, { "name": "SAB-185 (10,240 Units/kg)", "type": "BIOLOGICAL" }, { "name": "CASIRIVIMAB + IMDEVIMAB", "type": "DRUG" }, { "name": "Placebo for Bamlanivimab 7000mg", "type": "DRUG" }, { "name": "Placebo for Bamlanivimab 700mg", "type": "DRUG" }, { "name": "Placebo for BRII-196+BRII-198", "type": "DRUG" }, { "name": "Placebo for SNG001", "type": "DRUG" }, { "name": "Placebo for Camostat", "type": "DRUG" }, { "name": "Placebo for SAB-185 (low dose)", "type": "DRUG" }, { "name": "Placebo for BMS-986414 + BMS-986413", "type": "DRUG" }, { "name": "Placebo for AZD7442 (IV)", "type": "DRUG" }, { "name": "Placebo for AZD7442 (IM)", "type": "DRUG" }, { "name": "Placebo for SAB-185 (high dose)", "type": "DRUG" }, { "name": "bamlanivimab 700mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4044, "start_date": "2020-08-19", "completion_date": "2023-06-20", "has_results": true, "last_update_posted_date": "2024-08-02", "last_synced_at": "2026-10-07T09:07:26.139Z", "location_count": 207, "location_summary": "Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04518410" }, { "nct_id": "NCT07639359", "title": "Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Critical Illness", "Depressive Symptoms" ], "interventions": [ { "name": "Ketamine (0.5 mg/kg)", "type": "DRUG" }, { "name": "Normal Saline (0.9% NaCl)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hospital Italiano de Buenos Aires", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 50, "start_date": "2026-05-14", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-07T09:07:26.139Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07639359" }, { "nct_id": "NCT00225732", "title": "Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Normal saline as placebo comparator", "type": "OTHER" }, { "name": "Intravenous ibuprofen", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Cumberland Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 319, "start_date": "2005-01", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2016-06-22", "last_synced_at": "2026-10-07T09:07:26.139Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00225732" }, { "nct_id": "NCT05136053", "title": "A Study Investigating Lu AG22515 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Lu AG22515", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Immune System Activator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "19 Years to 60 Years" }, "enrollment_count": 58, "start_date": "2022-03-18", "completion_date": "2023-08-05", "has_results": false, "last_update_posted_date": "2023-08-28", "last_synced_at": "2026-10-07T09:07:26.139Z", "location_count": 2, "location_summary": "Long Beach, California • Secaucus, New Jersey", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Secaucus", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05136053" }, { "nct_id": "NCT01954082", "title": "Inositol to Reduce Retinopathy of Prematurity", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Retinopathy of Prematurity (ROP)" ], "interventions": [ { "name": "myo-Inositol 5% Injection", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NICHD Neonatal Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Hours", "maximum_age": "72 Hours", "sex": "ALL", "summary": "12 Hours to 72 Hours" }, "enrollment_count": 638, "start_date": "2014-04-17", "completion_date": "2016-12-31", "has_results": true, "last_update_posted_date": "2019-03-22", "last_synced_at": "2026-10-07T09:07:26.139Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01954082" }, { "nct_id": "NCT04722666", "title": "Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder With Suicidal Ideation With Intent" ], "interventions": [ { "name": "MIJ821 Intravenous Injection", "type": "DRUG" }, { "name": "Placebo Intravenous Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 199, "start_date": "2021-07-20", "completion_date": "2023-09-26", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-07T09:07:26.139Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Farmington, Connecticut • Oakland Park, Florida + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Oakland Park", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04722666" }, { "nct_id": "NCT02780583", "title": "Treatment of Macrophage Activation Syndrome (MAS) With Anakinra", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Macrophage Activation Syndrome" ], "interventions": [ { "name": "kineret", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 9, "start_date": "2016-05-15", "completion_date": "2024-04-30", "has_results": false, "last_update_posted_date": "2024-08-01", "last_synced_at": "2026-10-07T09:07:26.139Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02780583" }, { "nct_id": "NCT04879628", "title": "Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "SAR441344 IV", "type": "DRUG" }, { "name": "placebo IV", "type": "DRUG" }, { "name": "SAR441344 SC", "type": "DRUG" }, { "name": "placebo SC", "type": "DRUG" }, { "name": "MRI contrast-enhancing preparations", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 129, "start_date": "2021-06-07", "completion_date": "2027-08-23", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-07T09:07:26.139Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Tampa, Florida • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879628" }, { "nct_id": "NCT05952986", "title": "A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "FB825 or Placebo in subcutaneous route", "type": "DRUG" }, { "name": "FB825 in intravenous route", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oneness Biotech Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 22, "start_date": "2023-05-03", "completion_date": "2024-03-26", "has_results": false, "last_update_posted_date": "2024-01-26", "last_synced_at": "2026-10-07T09:07:26.139Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05952986" } ] }